Gilead Sciences Ownership
| GILD Stock | USD 90.19 0.43 0.48% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 1.3 B | Current Value 1.3 B | Avarage Shares Outstanding 1.5 B | Quarterly Volatility 208.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Gilead |
Gilead Stock Ownership Analysis
About 88.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.53. Gilead Sciences last dividend was issued on the 13th of December 2024. The entity had 2:1 split on the 28th of January 2013. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 14400 people. To learn more about Gilead Sciences call Daniel ODay at 650 574 3000 or check out https://www.gilead.com.Besides selling stocks to institutional investors, Gilead Sciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Gilead Sciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Gilead Sciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Gilead Sciences Quarterly Liabilities And Stockholders Equity |
|
Gilead Sciences Insider Trades History
Less than 1% of Gilead Sciences are currently held by insiders. Unlike Gilead Sciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Gilead Sciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Gilead Sciences' insider trades
Gilead Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gilead Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gilead Sciences backward and forwards among themselves. Gilead Sciences' institutional investor refers to the entity that pools money to purchase Gilead Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 14.1 M | Northern Trust Corp | 2024-09-30 | 12.5 M | Legal & General Group Plc | 2024-06-30 | 12.4 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 11.7 M | Amundi | 2024-06-30 | 11.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 10.6 M | Amvescap Plc. | 2024-06-30 | 10.1 M | Goldman Sachs Group Inc | 2024-06-30 | 9.2 M | Pacer Advisors, Inc. | 2024-06-30 | 7.9 M | Blackrock Inc | 2024-06-30 | 120.6 M | Vanguard Group Inc | 2024-09-30 | 115.3 M |
Gilead Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gilead Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrew Dickinson over three months ago Disposition of 3025 shares by Andrew Dickinson of Gilead Sciences subject to Rule 16b-3 | ||
Sandra Patterson over three months ago Disposition of 748 shares by Sandra Patterson of Gilead Sciences subject to Rule 16b-3 | ||
Johanna Mercier over six months ago Acquisition by Johanna Mercier of 20086 shares of Gilead Sciences subject to Rule 16b-3 | ||
Kevin Young over six months ago Acquisition by Kevin Young of 26000 shares of Gilead Sciences subject to Rule 16b-3 |
Gilead Sciences' latest congressional trading
Congressional trading in companies like Gilead Sciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Gilead Sciences by those in governmental positions are based on the same information available to the general public.
| 2024-06-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-06-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-05-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2020-09-29 | Representative Ed Perlmutter | Acquired Under $15K | Verify | ||
| 2019-11-13 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
| 2018-10-18 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2018-10-17 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2018-08-10 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2018-08-09 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2018-05-22 | Senator Angus King | Acquired Under $15K | Verify | ||
| 2017-10-12 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify | ||
| 2017-10-11 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2017-04-11 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
| 2017-04-10 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
| 2017-01-05 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
| 2016-08-22 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2016-08-21 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2016-02-03 | Senator James Inhofe | Acquired $15K to $50K | Verify | ||
| 2015-07-09 | Senator James Inhofe | Acquired $50K to $100K | Verify |
Gilead Sciences Outstanding Bonds
Gilead Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gilead Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gilead bonds can be classified according to their maturity, which is the date when Gilead Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| GILEAD SCIENCES INC Corp BondUS375558AX11 | View | |
| GILEAD SCIENCES INC Corp BondUS375558AZ68 | View | |
| GILEAD SCIENCES INC Corp BondUS375558AS26 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BK80 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BJ18 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BM47 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BA09 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BG78 | View |
Gilead Sciences Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of November 2024 Other Reports | ViewVerify | |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.